Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Elanders AB: Report from the Annual General Meeting 2024
-
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
-
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023
-
Form 8.3 - Tritax Big Box Reit Plc
-
Form 8.3 - Hipgnosis Songs Fund Limited
-
Form 8.3 - Mattioli Woods
-
Alliance Trust PLC - Net Asset Value
-
Lakeland Bancorp Announces First Quarter Results
-
3Daughters Named “Startup of the Year” at BioLabs Philadelphia Investor Day 2024
-
Asset Entities Announces Second Episode of "The Lounge" Podcast with Music Industry Legend Jeff Blue
-
DRYWORLD and Renegade Territory Enter “Era-Defining” Partnership With Grammy-Award Winner, OPLUS
-
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
-
ContextLogic Announces Stockholder Approval of Transaction with Qoo10
-
Asset Entities Announces Second Episode of "The Lounge" Podcast with Music Industry Legend Jeff Blue
-
Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination
-
Form 8.3 - Lok’n Store Group PLC
-
Preliminary Results for the Year Ended 31 December 2023
-
Form 8.3 - Balanced Commercial Property Trust Limited
-
Form 8.3 - ABRDN European Logistics Income Plc
-
Flexion awarded contract to revolutionize Head Start’s Data Management System
-
Silver Mountain Announces Upsize of Previously Announced Public Offering of Units to $9 Million
-
Form 8.3 - [Insert name of offeree or offeror]
-
SL Green Realty Corp. Announces Common Stock Dividend
-
Webuy Announces Filing of 2023 Annual Report with the SEC, Launches Travel Business in Indonesia, and Expands into Insurance Referral Program
-
Webuy Announces Filing of 2023 Annual Report with the SEC, Launches Travel Business in Indonesia, and Expands into Insurance Referral Program
-
Huize Partners with PICC Life Insurance to Launch “i Wu You – Low-Threshold Edition” – A Customized Critical Illness Insurance Product
-
Gate.io Introduces Quant Fund - A New Era of Wealth Management for Digital Assets
-
Auction result of Treasury Bonds - RIKB 27 0415
-
Perella Weinberg to Announce First Quarter 2024 Financial Results and to Host Conference Call on May 3, 2024
-
Form 8.3 - Mattioli Woods plc
-
Netcompany - Final transactions in connection with share buyback programme
-
Middlefield Canadian Income PCC: Net Asset Value(s)
-
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
-
Huize Holding Limited Files 2023 Annual Report on Form 20-F
-
Invesco Ltd: Form 8.3 - Mondi PLC
-
The deadline for Valoe’s restructuring programme extended until 14.6.2024. Valoe has secured financing for the duration of the proceedings and continues to negotiate longer-term financing.
-
Invesco Ltd: Form 8.3 - DS Smith PLC
-
Merlin Chain Launches MERL: A Major Leap Forward in Bitcoin Layer 2 Solutions
-
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
-
Merlin Chain Launches MERL: A Major Leap Forward in Bitcoin Layer 2 Solutions
-
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
-
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
-
Balchem Corporation Announces Quarterly Conference Call for First Quarter Financial Results on May 3, 2024
-
Giambattista Valli dazzles Barcelona during the Bridal Night
-
Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PAPER CO - Ordinary Shares
-
WOO X Research revises BTC price prediction and Q2 industry outlook, one day before BTC Halving
-
Dimensional Fund Advisors Ltd. : Form 8.3 - MONDI PLC - Ordinary Shares
-
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
-
Dimensional Fund Advisors Ltd. : Form 8.3 - DS SMITH PLC - Ordinary Shares
-
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

